Press Releases Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-10 pm EDT			After market 04:31:45 pm
0.4859 ^USD	+2.06%		0.475	-2.24%

01:03pm	Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate	CI
Jul. 05	Unicycive Therapeutics Files Shelf Registration for Sale of Up to 50 Million Shares by Stockholders	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)	07:03am	AQ
Unicycive Therapeutics Joins Russell Microcap® Index	Jul. 01	AQ
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial	Jun. 25	AQ
Unicycive Therapeutics : Oxylanthanum Carbonate (OLC) UNI OLC 201 Pivotal Trial Topline Data	Jun. 24	PU
Unicycive Therapeutics : June 2024 Corporate Presentation	Jun. 03	PU
Unicycive Therapeutics : May 2024 Corporate Presentation	May. 29	PU
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress	May. 28	AQ
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference	May. 23	AQ
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting	May. 15	AQ
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update	May. 13	AQ
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	Apr. 10	AQ
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update	Mar. 28	AQ
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress	Mar. 25	AQ
Unicycive Announces $50 Million Private Placement	Mar. 14	AQ
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference	Mar. 13	AQ
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)	Mar. 07	AQ
Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?	Mar. 06	PR
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients	Mar. 04	AQ
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting	Feb. 14	AQ
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference	Jan. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Press Releases

Filters